CA
MLYS icon

CHI Advisors’s Mineralys Therapeutics MLYS Stock Holding History

CHI Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$5.41M Buy
+568,379
New +$7.41M 2.14% 11

Other funds holding MLYS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CHI Advisors's MLYS Position: Q3 2023 in Review

CHI Advisors opened a new position in Mineralys Therapeutics (MLYS) in Q3 2023: 568,379 shares worth $5.41M. The stake represents 2.14% of the portfolio and ranks #11 among its holdings.

77 funds tracked by Wall St. Rank hold MLYS as of Q3 2023.

  • CHI Advisors held 568,379 shares of Mineralys Therapeutics worth $5.41M as of Q3 2023.
  • Mineralys Therapeutics was a new CHI Advisors position in Q3 2023.
  • Mineralys Therapeutics made up 2.14% of CHI Advisors's portfolio in Q3 2023, its #11 holding.
  • 77 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2023.

Based on CHI Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.